#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	17156	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2050	830.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1414	1414	C	1003	C	950	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	17156	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2050	830.6	0	HET	.	.	.	C326T	.	326	326	C	556	556	C	946	C,T	684,191	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30696	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3653	838.2	0	.	n	.	0	T695C	SNP	695	695	T	1035	1035	C	959	C,T	908,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30696	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3653	838.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1677	1677	A	999	A	943	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30696	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3653	838.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2311	2311	C	922	C,T	862,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30696	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3653	838.2	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2385	2385	G	960	G,A,T	908,4,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30696	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3653	838.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2937	2937	C	967	C,A	917,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2516	folP	852	852	100.0	folP.l15.c4.ctg.1	1427	174.8	1	SNP	p	R228S	1	.	.	682	684	AGC	984	986	AGC	254;256;260	A;G;C	238;238;243	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6280	gyrA	2751	2751	99.82	gyrA.l15.c30.ctg.1	3416	183.5	1	SNP	p	S91F	0	.	.	271	273	TCC	584	586	TCC	231;232;236	T;C;C	213;215;219	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6280	gyrA	2751	2751	99.82	gyrA.l15.c30.ctg.1	3416	183.5	1	SNP	p	D95N	0	.	.	283	285	GAC	596	598	GAC	230;231;231	G;A;C	212;213;213	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6280	gyrA	2751	2751	99.82	gyrA.l15.c30.ctg.1	3416	183.5	1	SNP	p	D95G	0	.	.	283	285	GAC	596	598	GAC	230;231;231	G;A;C	212;213;213	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	1964	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1170	166.5	1	SNP	p	G45D	1	.	.	133	135	GAC	430	432	GAC	238;240;239	G;A;C	229;227;231	mtrR.WHO_K_01388:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1048	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	957	108.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6044	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2824	213.0	1	SNP	p	D86N	0	.	.	256	258	GAC	568	570	GAC	279;277;278	G;A;C	262;259;262	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6044	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2824	213.0	1	SNP	p	S87W	0	.	.	259	261	AGT	571	573	AGT	282;280;285	A;G;T	263;262;263	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6044	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2824	213.0	1	SNP	p	S87I	0	.	.	259	261	AGT	571	573	AGT	282;280;285	A;G;T	263;262;263	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6044	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2824	213.0	1	SNP	p	S87R	0	.	.	259	261	AGT	571	573	AGT	282;280;285	A;G;T	263;262;263	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	6044	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2824	213.0	1	SNP	p	S88P	0	.	.	262	264	TCC	574	576	TCC	283;285;285	T;C;C	261;260;263	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5152	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2752	186.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1569	1571	GGC	266;264;262	G;G;C	247;245;244	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1378	1380	GCA	228;232;234	G;C;A	211;212;220	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1381	1383	ATC	237;238;240	A;T;C	223;222;223	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1393	1395	GTG	245;246;244	G;T;G	226;225;229	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1393	1395	GTG	245;246;244	G;T;G	226;225;229	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1897	1899	ACC	259;261;260	A;C;C	236;245;245	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1951	1953	GCG	233;233;233	G;C;G	209;187;197	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1951	1953	GCG	233;233;233	G;C;G	209;187;197	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2074	2076	GGC	175;175;175	G;G;C	163;162;162	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2083	2085	GGC	174;174;173	G;G;C	159;157;157	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4462	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2586	171.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2101	2103	CCG	156;156;156	C,G;C;G	119,7;117;120	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6402	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3140	203.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2696	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1866	143.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	484	484	C	203	C	187	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	T87A	NONSYN	259	261	ACT	509	511	GCT	228;230;232	G;C;T	208;209;210	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	515	517	AGC	228;225;224	A;G;C,T	210;208;207,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	607	608	CG	234;232	C,T;G	226,1;226	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	610	612	CAG	234;231;226	C;A;G	223;220;214	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	614	616	AAA	233;232;236	A;A;A	223;222;226	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	N134S	NONSYN	400	402	AAT	650	652	AGT	220;219;221	A;G;T	211;211;214	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	E137K	NONSYN	409	411	GAA	659	661	AAA	225;225;224	A;A;A	218;219;216	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	677	679	GAA	216;221;228	G;A;A	205;211;217	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	701	703	GCA	251;256;259	G;C;A,C	229;239;240,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	809	811	CAA	238;234;234	C;A;A	230;227;228	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	N189S	NONSYN	565	567	AAC	815	817	AGC	234;232;234	A;G;C	225;223;224	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	M209I	NONSYN	625	627	ATG	875	877	ATC	247;253;256	A;T;C	232;232;235	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	0	.	p	.	0	E210fs	FSHIFT	628	628	G	878	878	G	258	G	237	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	1	SNP	p	G120K	1	.	.	358	360	AAG	607	609	CGG	234;232;233	C,T;G;G	226,1;226;226	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	1	SNP	p	D121N	0	.	.	361	363	GAC	610	613	CGC	234;226;227	C;G;C	223;214;218	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	3092	porB1b	1041	1041	96.95	porB1b.l15.c17.ctg.1	1441	213.1	1	SNP	p	A121D	1	.	.	361	363	GAC	610	613	CGC	234;226;227	C;G;C	223;214;218	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11510	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4780	239.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1892	1894	AAT	250;253;250	A,C;A;T	238,1;242;238	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1220	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1000	121.2	1	SNP	p	V57M	1	.	.	169	171	ATG	524	526	ATG	259;259;256	A;T;G	246;245;243	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
